Gilead Reports Results of Biktarvy (Bictegravir, Emtricitabine, Tenofovir Alafenamide) in P-III Study 1490 for Patients with HIV-1

 Gilead Reports Results of Biktarvy (Bictegravir, Emtricitabine, Tenofovir Alafenamide) in P-III Study 1490 for Patients with HIV-1

Gilead Reports Results of Biktarvy (Bictegravir, Emtricitabine, Tenofovir Alafenamide) in P-III Study 1490 for Patients with HIV-1

Shots:

  • The P-III 1490 Study involves assessing of Biktarvy (BIC 50/FTC 200/TAF 25mg tablets) vs dolutegravir and emtricitabine/tenofovir alafenamide (50 mg) (DTG+FTC/TAF) in ratio (1:1) patients with HIV-1 naive to HIV therapy in adults for 96 wks.
  • P-III Study 1490 results: HIV-1 RNA levels less than 50 copies/mL 95%; well-tolerated with low discontinuations @48 wks. & 96wks. (1%, 2% vs 4%, 2%) presented at HIV Glasgow 2018. The ongoing 1490 trial will continue for 144 wks.
  • Biktarvy includes a boxed warning regarding its discontinuation in the US product label for risk of severe acute exacerbations of hepatitis B in patients with HIV-1 and HBV and is available in Australia, Canada, EU, Hong Kong and the US

Click here to read full press release/ article | Ref: Gilead| Image: PMLiVE

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post